GlassScriptPhysician profile
Heidi K Straughn
NPI 1588663884
$29,345.61
in general payments reported to CMS, 2019-2025
46 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $503 · 2021: $768 · 2022: $729 · 2023: $1,718 · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $2,132 · Honoraria: $350 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,000.00 |
| Food and Beverage | $2,131.84 |
| Honoraria | $350.00 |
| Education | $228.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $24,101.00 | 2022-2025 | Gelpoint V-Path |
| Abbvie INC. | $545.81 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $494.28 | 2019-2025 | Veozah, Myrbetriq |
| Meditrina | $361.31 | 2025 | |
| Hologic Sales and Service, LLC | $359.82 | 2019-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Organon LLC | $331.21 | 2022-2025 | Nexplanon, Jada System |
| Novo Nordisk INC | $311.08 | 2019-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $293.75 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $268.90 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.80 | 2019-2025 | |
| Myovant Sciences INC. | $161.80 | 2021-2022 | |
| Therapeuticsmd, INC. | $151.24 | 2019-2022 | |
| Shield Therapeutics INC | $147.30 | 2022-2025 | Accrufer |
| Eisai INC. | $116.49 | 2020-2021 | |
| Amgen INC. | $112.71 | 2019-2023 | Prolia, Evenity |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Straughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.